SCHEDULE: Auctus Fund Discloses 9.9% Stake in BioRestorative

Auctus Fund, LLC and its affiliates have reported a 9.9% beneficial ownership stake in BioRestorative Therapies, Inc. through common stock and warrant holdings.

Summary

• Auctus Fund, LLC, along with Auctus Fund Management LLC, Alfred Sollami, and Louis Posner, filed a Schedule 13G reporting a 9.9% beneficial ownership in BioRestorative Therapies, Inc.
• The total beneficial ownership of 2,699,470 shares consists of 1,155,914 shares of common stock and 1,543,556 shares issuable upon the exercise of warrants.
• The reporting persons have shared voting and dispositive power over the entire 2,699,470 share position.
• The filing notes a 9.99% blocker provision on the warrants, which limits the immediate exercisability of additional shares to maintain the 9.9% ownership threshold.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure; it confirms institutional interest but does not signal a change in company strategy or operational performance.

Positives

• Institutional investment interest from Auctus Fund, LLC suggests confidence in the company's long-term prospects.
• The 9.9% stake indicates a significant position held by an investment firm, which can provide liquidity and market validation.

Negatives

• The presence of a large warrant position (1,543,556 shares) creates potential future dilution for existing shareholders upon exercise.
• The 9.9% ownership level is close to the 9.99% blocker threshold, which may constrain the investor's ability to increase their position without further regulatory filings.

Risks

• Potential dilution of common stock value if the 1,543,556 warrants are exercised.
• Market volatility associated with large institutional holdings and potential future divestment.

Future Outlook

The reporting persons state that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Management Comments

• The reporting persons expressly disclaim beneficial ownership over any of the securities reported in this statement, and the filing shall not be construed as an admission of beneficial ownership.

Industry Context

StockSavvy.ai notes that institutional filings like this are common in the biotech sector, where firms often provide capital through structured instruments like warrants to support clinical development and operations.

Comparison to Industry Standards

• The 9.9% ownership threshold is a standard benchmark for institutional investors to avoid triggering more stringent 'control' reporting requirements under SEC rules.
• The use of warrant blockers at 9.99% is a standard practice in small-cap biotech financing to manage regulatory compliance and prevent inadvertent changes in control.

Stakeholder Impact

• Shareholders should be aware of the potential for future dilution from the exercise of 1,543,556 warrants.
• The presence of a significant institutional holder may provide a floor for the stock price but could also lead to volatility if the holder decides to exit.

Next Steps

• Monitoring for any future amendments to the Schedule 13G if the reporting persons increase or decrease their position.
• Tracking potential warrant exercises that could impact share count and dilution.

Key Dates

Recommendation

The filing is a standard disclosure of institutional ownership. While it confirms external interest, it does not provide new information regarding the company's fundamental business performance or clinical trial progress, warranting a hold position until further operational updates are provided.

Keywords

BioRestorative Therapies, Auctus Fund, Schedule 13G, Beneficial Ownership, Biotech, Warrants, Equity Dilution